PCT Stem Cells 2016

PeproTech at Stem Cells 2016

Sponsor networking 2016 stem cells

For three days, the global biologics community descends on Basel. With the co-location of fantastic events – the European Antibody Congress, the World Biosimilars Congress, the HPAPI World Congress and the World  Immunotherapy Congress – comes over 180 world-leading speakers and hundreds of brand new case studies explored.


  • Putting antibody development intothe wider healthcare context
  • Antibody-drug conjugates
  • Target discover and computationalbiology
  • Bispecific antibodies


  • Protein engineering
  • Protein expression
  • Analytics
  • Immunogenicity and bioanalytics
  • Immunotherapies

DAY 3 

  • Platform technology showcase
  • Clinical development
  • CMC and developability
  • Bioprocessing and production



Alain Beck , Senior Director, NBEs Analytical Chemistry, Pierre Fabre, Associate Editor, mAbs
Alain Vertes , Managing Director, NxR Biotechnologies
Alexey Rak , Head of Bio Structure and Biophysics, Sanofi R&D
A lfonso Quintas , Head of Clinical Research, Cell Therapies Unit, GSK
André Choulika , CEO, Cellectis
Andrea Gonzalez-Munoz , Research Associate, MedImmune
Andreas Plückthun , Professor of Biochemistry, Director, Department of Biochemistry, University of Zurich
Annelise Vuidepot , VP, Head of Oncology Pipeline and Research, Immunocore
Antoine Deslandes , Scientific Advisor, Translational Medicine and Early Development, Sanofi
Carsten Kranz , Drug Metabolism and Pharmacokinetics, Novartis Pharma AG
Christian Klein , Head of Oncology Programs, Roche
Christian Rommel , Global Head of Oncology Discovery, Roche
Christoph Merten , Group Leader Microfluidics, European Molecular Biology Laboratory
Christoph Rader , Associate Professor, Department of Immunology and Microbiology, The Scripps Research Institute
Dario Neri, Founder , Philogen; Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich
David Brindley , Senior Research Fellow in Healthcare Translation, Department of Paediatrics, University of Oxford
David Gilham , Vice President of Research & Development, Celyad
David Meininger , Chief Business Officer, Trianni
Fabian Richter , Post-Doc, University of Stuttgart
Feng Wang , Principal Investigator, CaliBR
Frank Walsh , CEO, Ossianix
Gregory Winter , Master of Trinity, Cambridge University, Founder and Co-Director, Bicycle Therapeutics
Hans G. Klingemann , Vice President, Research & Development, NantKwest
Haruki Hasegawa , Principal Scientist, Department of Therapeutic Discovery, Amgen
Hervé Watier , Co-ordinator of the MAbImprove LabEx, University of Tours
Ivan Mascanfroni, Senior Scientist, Immunology Biologics, AbbVie Bioresearch Centre
Janice Reichert , Executive Director, The Antibody Society; Editor-in-Chief, mABs
Jens Wuerthner , Assistant Vice President, Head of Clinical Development – EU, ADC Therapeutics
Jerald Sadoff , Senior Advisor Vaccine Development, Senior Clinical Advisor RSV, Janssen Infectious Diseases and Vaccines
Jeremy Clarke , Director of Commercial Development, Asterand
Jijie Gu , Research Fellow – Immunotherapy Discovery & Head of Oncology Biologics Discovery, Global Biologics, Abbvie
John Delaney , Executive Director of Research, Amgen
Jim Freeth, Managing Director, Retrogenix
Jiri Kovarik , Senior Research Investigator, Novartis Institutes for Biomedical Research
Karin Jooss , Chief Scientific Officer, Gritstone Oncology
Katherine (Kangwen) Deng , Senior Scientist, AbbVie Bioresearch Centre
Lars Linden , Head of Protein Biochemistry, Bayer AG
Lee Dawson , Scientist, Asterand
Lutz Jermutus , Senior Director, R&D, MedImmune
Marie-Paule Lefranc , Chair of Immunogenetics and Immunoinformatics, University of Montpellier
Marjorie Shapiro , Chief of Laboratory of Molecular and Developmental Immunology, FDA
Martin Treder , Chief Scientific Officer, Affimed
Michael DeRidder , Senior Director, Early Pipeline Commercial Strategy, Oncology Cell Therapy, GSK
Michael Schopperle , Chief Executive Officer, CureMeta
Michael Streit , Senior Director, Clinical Leader Research, Translational Medicine and Early Development, Oncology, Janssen
Oliver Spadiut , Assistant Professor, Integrated Bioprocess Development, TU Wien
Patrick Mehlen , Director of Translational Research, Centre Léon Bérard, Chief Executive Officer, Netris Pharma
Peter Ellmark , Principal Scientist, Immuno-Oncology, Alligator Bioscience
Puja Sapra , Vice President and Chief Scientific Officer, Targeted therapeutics Discovery, Oncology Research, Pfizer Worldwide Research and Development
Representative, Amgen
Renier Brentjens , Director, Cellular Therapeutics, Memorial Sloane Kettering Cancer Center
Robert Boyd , Scientific Director, Oxford BioTherapeutics UK
Roy Baynes , Senior Vice President & Head, Global Clinical Development, Chief Medical Officer, MSD
Sai Reddy , Assistant Professor, ETH Zurich
Sarah Cianferani , Research Director, University of Strasbourg
Sidath Katagampola
, Biomarker Development Sciensist, Centre for Drug Development, Cancer Research UK
Scott Dylla , CSO, Abbvie Stemcentrx

Jerald Sadoff , Senior Advisor Vaccine Development, Senior Clinical Advisor RSV, Janssen Infectious Diseases and Vaccines
Jeremy Clarke , Director of Commercial Development, Asterand
Jijie Gu , Research Fellow – Immunotherapy Discovery & Head of Oncology Biologics Discovery, Global Biologics, Abbvie
J oern Schmitz , Head, Department of Immunotherapy, Fraunhofer IME
Senior Representative, Batavia
Senior Representative, CMC Biologics
Senior Representative, Fujifilm Diosynth Biotechnologies UK
Senior Representative, Immunogen
Senior Representative, KBI
Senior Representative, Nanotemper
Senior Representative, MaxCyte
Senior Representative, PALL
Senior Representative, Sartorius
Seth Ettenberg , CSO, Unum Therapeutics
Shane Olwill , Head of Immuno-Oncology, Pieris Pharmaceuticals
Stefan Dübel , Director, Department of Biotechnology, Technnische Universität Braunschweig
Steffen Hartmann , Global Head of Developability Assessment, Integrated Biologics Profiling, Novartis
Tim MacLachlan , Global Head of Biologics Safety Assessment, Novartis Institutes for BioMedical Research
Timo K. Van den Berg , Professor of Immunotherapy, Sanquin Research and Landsteiner Laboratory
Ulf Grawunder , CEO, NBE Therapeutics
Ulrich Brinkmann , Scientific Director, Roche Pharma Research & Early Development, Roche Innovation Centre Munich
Victor Obungu , Principal Research Scientist, Eli Lilly and Company
William Dall’Acqua , VP, Antibody Discovery and Protein Engineering,



To sponsor or exhibit contact Derek Cavanagh on 
or email